NEXTBio Capital Management LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), NEXTBio Capital Management LP reported 22 stock positions worth $217.4 million. Its top holding was Protagonist Therapeutics (PTGX) at 12.4% of the portfolio, followed by Shattuck Labs (STTK, 11.9%) and Compass Pathways (CMPS, 11.6%). Compared with Q1 2026, it opened 3 new positions, sold out of 5, added to 7 and reduced 5. The biggest buy was Structure Therapeutics (GPCR, shares +135%) and the biggest sale an exit from Terns Pharmaceuticals (TERN).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0002038158
- Portfolio Value
- $217.4M (Q2 2026)
- SEC Filing
- 0001172661-26-003533 ↗ filed Aug 14, 2026
Holdings Value
Holdings 22 stocks · $217.4M
| PTGX Protagonist Therapeutics Inc. | 12.37% | 219,333 | $26.9M | Reduce -4.5% |
| STTK Shattuck Labs Inc. | 11.90% | 3,727,348 | $25.9M | Add +18.3% |
| CMPS Compass Pathways PLC | 11.56% | 1,775,759 | $25.1M | Reduce -12.2% |
| GPCR Structure Therapeutics Inc. | 7.71% | 312,496 | $16.8M | Add +134.5% |
| VOR Vor Biopharma Inc. | 7.53% | 889,164 | $16.4M | Reduce -11.1% |
| RYTM Rhythm Pharmaceuticals Inc. | 6.73% | 131,758 | $14.6M | Add +4.5% |
| PVLA Palvella Therapeutics Inc. | 6.32% | 89,909 | $13.7M | Add +8.7% |
| XENE Xenon Pharmaceuticals Inc. | 5.09% | 183,225 | $11.1M | No change |
| ZBIO Zenas Biopharma Inc. | 4.98% | 426,736 | $10.8M | No change |
| ORIC Oric Pharmaceuticals Inc. | 3.52% | 706,124 | $7.6M | Add +34.9% |
| IVA Inventiva SA - ADR | 3.11% | 1,787,984 | $6.8M | Add +34.1% |
| CBIO Crescent Biopharma Inc. | 3.09% | 372,856 | $6.7M | No change |
| PCVX Vaxcyte Inc. | 2.87% | 107,223 | $6.2M | Add +12.6% |
| COGT Cogent Biosciences Inc. | 2.33% | 131,075 | $5.1M | Reduce -0.1% |
| VSTM Verastem Inc. | 2.30% | 1,306,800 | $5.0M | No change |
| IRON Disc Medicine Inc. | 1.77% | 52,655 | $3.9M | No change |
| PHVS Pharvaris NV | 1.72% | 108,055 | $3.7M | New |
| ZLAB Zai Lab Ltd.-ADR | 1.60% | 183,362 | $3.5M | No change |
| BIOA Bioage Labs Inc. | 1.14% | 100,732 | $2.5M | New |
| LBRX LB Pharmaceuticals Inc. | 1.02% | 68,249 | $2.2M | New |
| EVMN Evommune Inc. | 0.73% | 119,063 | $1.6M | Reduce -35.3% |
| ACET Adicet Bio Inc. | 0.63% | 157,827 | $1.4M | No change |
Portfolio Sells Q1 2026 → Q2 2026
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −14.80 |
| CMPX Compass Therapeutics Inc. | Sold out | 0.00% | −2.08 |
| OCS Oculis Holding AG | Sold out | 0.00% | −1.85 |
| EVMN Evommune Inc. | Reduce -35.3% | 0.73% | −1.24 |
| KALV Kalvista Pharmaceuticals Inc. | Sold out | 0.00% | −1.23 |
| SMMT Summit Therapeutics Inc. | Sold out | 0.00% | −0.79 |
| VOR Vor Biopharma Inc. | Reduce -11.1% | 7.53% | −0.75 |
| COGT Cogent Biosciences Inc. | Reduce -0.1% | 2.33% | −0.01 |
| PTGX Protagonist Therapeutics Inc. | Reduce -4.5% | 12.37% | +1.13 |
| CMPS Compass Pathways PLC | Reduce -12.2% | 11.56% | +6.37 |
Portfolio Buys Q1 2026 → Q2 2026
| GPCR Structure Therapeutics Inc. | Add +134.5% | 7.71% | +4.73 |
| STTK Shattuck Labs Inc. | Add +18.3% | 11.90% | +2.49 |
| PHVS Pharvaris NV | New | 1.72% | +1.72 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +4.5% | 6.73% | +1.64 |
| PVLA Palvella Therapeutics Inc. | Add +8.7% | 6.32% | +1.53 |
| BIOA Bioage Labs Inc. | New | 1.14% | +1.14 |
| LBRX LB Pharmaceuticals Inc. | New | 1.02% | +1.02 |
| ORIC Oric Pharmaceuticals Inc. | Add +34.9% | 3.52% | +0.44 |
| PCVX Vaxcyte Inc. | Add +12.6% | 2.87% | +0.30 |
| IVA Inventiva SA - ADR | Add +34.1% | 3.11% | −0.33 |